New Zealand
5 Vaccines Approved for Use in New Zealand
Protein Subunit
Novavax
Nuvaxovid
Approved in 40 countries
22 trials in 14 countries
Approval Source: ir.novavax.com
RNA
Pfizer/BioNTech
Comirnaty
Approved in 149 countries
100 trials in 31 countries
Approval Source: medsafe.govt.nz
Non Replicating Viral Vector
Janssen (Johnson & Johnson)
Ad26.COV2.S
Approved in 111 countries
23 trials in 23 countries
Approval Source: reuters.com
Non Replicating Viral Vector
Oxford/AstraZeneca
Vaxzevria
Approved in 149 countries
73 trials in 34 countries
Approval Source: reuters.com
Non Replicating Viral Vector
Janssen (Johnson & Johnson)
Jcovden
Approved in 113 countries
26 trials in 25 countries
Approval Source: reuters.com
10 in Clinical Trials in New Zealand
Protein Subunit
Jiangsu Rec-Biotechnology Co Ltd
ReCOV
6 trials in 3 countries
Protein Subunit
SK Bioscience Co Ltd
GBP510
6 trials in 6 countries
Non Replicating Viral Vector
Oxford/AstraZeneca
Vaxzevria
Approved in 149 countries
73 trials in 34 countries
Inactivated
Valneva
VLA2001
Approved in 33 countries
9 trials in 4 countries
Inactivated
Valneva
VLA2101
Protein Subunit
VaxForm
CoV2-OGEN1
Protein Subunit
Yisheng Biopharma
PIKA COVID-19 Vaccine
3 trials in 1 country
Protein Subunit
Novavax
Nuvaxovid
Approved in 40 countries
22 trials in 14 countries
Protein Subunit
SK Bioscience Co Ltd
SKYCovione
Approved in 1 country
7 trials in 6 countries
Protein Subunit
Novavax
ICC Vaccine
3 trials in 2 countries